MabThera
NICE U-turn on Roche’s MabThera
May 25, 2011Sales and Marketing MabThera, NICE, Roche
NICE has provisionally recommended Roche’s MabThera as a maintenance therapy for blood cancer patients. The new draft guidance backs MabThera’s …
Roche’s MabThera successor shows phase II promise
December 6, 2010Research and Development, Sales and Marketing GA101, Genentech, GlycArt, MabThera, Roche, blood cancer, chronic lymphocytic leukaemia
The cancer drug Roche is developing as a second-generation successor to its blockbuster MabThera has shown promising results in a …
NICE recommends MabThera for non-Hodgkin’s lymphoma
December 6, 2010Sales and Marketing MabThera, NICE, Rituxan, Roche, non-Hodgkin’s lymphoma, rituximab
NICE has given a preliminary green-light to Roche’s MabThera for use as a maintenance therapy for non-Hodgkin’s lymphoma. The Institute’s …
MabThera gains maintenance therapy licence
October 29, 2010Medical Communications, Sales and Marketing MabThera, Rituxan, Roche, lymphoma
Roche’s MabThera has been approved as a maintenance therapy for follicular lymphoma, a common type of blood cancer. Maintenance treatment …
NICE approves trio of cancer drugs
July 28, 2010Sales and Marketing Iressa, MabThera, NICE, Xeloda
NICE has given its final recommendation to a trio of drugs for the treatment of various cancers, which means the …
NICE re-thinks arthritis guidance
June 25, 2010Sales and Marketing Enbrel, Humira, MabThera, NICE, Orencia, Remicade, TNF, rheumatoid arthritis
NICE has approved five rheumatoid arthritis treatments in certain circumstances after treatment with a tumour necrosis factor inhibitor has failed. …
Roche cancer drug gets NICE thumbs up
March 5, 2010Sales and Marketing MabThera, Roche
NICE has recommended Roche’s MabThera to treat patients with the most common form of leukaemia, relapsed or refractory chronic lymphocytic …
Rituxan gains approval for most common leukaemia
February 19, 2010Sales and Marketing FDA, MabThera, Rituxan, blood cancer
Roche’s blockbuster cancer treatment MabThera/Rituxan has been approved by the FDA for the treatment of adult leukaemia. The drug earned …
MabThera shows improved leukaemia survival benefits
December 14, 2009Sales and Marketing CLL, MabThera, Roche
MabThera/Rituxan is the first treatment to show improved survival in previously untreated patients with chronic lymphocytic leukaemia (CLL), according to …
Roche’s MabThera expands licence in leukaemia
September 4, 2009Research and Development, Sales and Marketing MabThera, Roche
MabThera has been approved in Europe for use in previously treated chronic lymphocytic leukaemia, which Roche says will offer new …
NICE approves MabThera for leukaemia
July 22, 2009Research and Development, Sales and Marketing MabThera, NICE
NICE has approved Roche's top-selling drug MabThera as a first-line treatment for the UK's most common type of leukaemia. The …
Latest content
